Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Taurolidine,Heparin Sodium
Therapeutic Area : Immunology
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Undisclosed
Deal Type : Agreement
CorMedix Inc. Announces New Commercial Agreement
Details : Through the agreement, Cordemix will supply DefenCath (taurolidine and heparin) to dialysis clinics for CRBSI in adult patients with kidney failure receiving chronic hemodialysis.
Product Name : Defencath
Product Type : Antibiotic
Upfront Cash : Undisclosed
September 19, 2024
Lead Product(s) : Taurolidine,Heparin Sodium
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Taurolidine,Heparin Sodium
Therapeutic Area : Immunology
Study Phase : Approved FDF
Sponsor : ARC Dialysis, LLC
Deal Size : Undisclosed
Deal Type : Agreement
CorMedix Inc. Announces Commercial Agreement With ARC Dialysis, LLC
Details : Through the agreement, the company will focus on the supply and commercialization of DefenCath (taurolidine and heparin) for the treatment of catheter-related bloodstream infections.
Product Name : Defencath
Product Type : Antibiotic
Upfront Cash : Undisclosed
August 04, 2024
Lead Product(s) : Taurolidine,Heparin Sodium
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Sponsor : ARC Dialysis, LLC
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Taurolidine,Heparin Sodium
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : CorMedix
Deal Size : Undisclosed
Deal Type : Agreement
CorMedix Inc. Announces Commercial Agreement With Top Tier Dialysis Provider
Details :
Product Name : DefenCath
Product Type : Antibiotic
Upfront Cash : Undisclosed
May 28, 2024
Lead Product(s) : Taurolidine,Heparin Sodium
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : CorMedix
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Taurolidine,Heparin Sodium
Therapeutic Area : Nephrology
Study Phase : Phase IV
Sponsor : RBC Capital Markets
Deal Size : $40.0 million
Deal Type : Public Offering
Details : CorMedix intends to use the net proceeds for the commercialization of Taurolock Hep500 (taurolidine), approved to be instilled into catheter-based devices for hemodialysis in order to maintain patency of the vascular access device.
Product Name : Defencath
Product Type : Antibiotic
Upfront Cash : Undisclosed
June 28, 2023
Lead Product(s) : Taurolidine,Heparin Sodium
Therapeutic Area : Nephrology
Highest Development Status : Phase IV
Sponsor : RBC Capital Markets
Deal Size : $40.0 million
Deal Type : Public Offering
Lead Product(s) : Lidocaine,Heparin Sodium
Therapeutic Area : Urology
Study Phase : Phase II
Sponsor : Vaneltix Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Hyloris Announces Enrolment of First Patient in a 4-Arm Clinical Trial of Alenura(TM)
Details :
Product Name : Alenura
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 22, 2023
Lead Product(s) : Lidocaine,Heparin Sodium
Therapeutic Area : Urology
Highest Development Status : Phase II
Sponsor : Vaneltix Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Taurolidine,Heparin Sodium
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
CorMedix Inc. Announces FDA Acceptance of Resubmission of New Drug Application for DefenCath
Details : DefenCath is a formulation of taurolidine and heparin with broad antimicrobial activity that is being investigated for use as a catheter lock solution, with the aim of reducing the risk of catheter-related bloodstream infections from central venous cathe...
Product Name : Defencath
Product Type : Antibiotic
Upfront Cash : Inapplicable
June 21, 2023
Lead Product(s) : Taurolidine,Heparin Sodium
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Taurolidine,Heparin Sodium
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
CorMedix Inc. Announces Resubmission of New Drug Application for DefenCath
Details : DefenCath™ is a formulation of taurolidine and heparin with broad antimicrobial activity that is being investigated for use as a catheter lock solution, with the aim of reducing the risk of catheter-related bloodstream infections from central venous ca...
Product Name : Defencath
Product Type : Antibiotic
Upfront Cash : Inapplicable
May 16, 2023
Lead Product(s) : Taurolidine,Heparin Sodium
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Taurolidine,Heparin Sodium
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : DefenCath™ is a formulation of taurolidine and heparin with broad antimicrobial activity that is being investigated for use as a catheter lock solution, with the aim of reducing the risk of catheter-related bloodstream infections from central venous ca...
Product Name : Defencath
Product Type : Antibiotic
Upfront Cash : Inapplicable
January 05, 2023
Lead Product(s) : Taurolidine,Heparin Sodium
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lidocaine,Heparin Sodium
Therapeutic Area : Urology
Study Phase : Phase II
Sponsor : Hyloris Pharmaceuticals
Deal Size : $6.7 million
Deal Type : Collaboration
Details : Under the terms of the agreement, Vaneltix will be responsible for the further development, manufacturing, regulatory affairs and commercialisation of AlenuraTM in collaboration with Hyloris.
Product Name : Alenura
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
December 17, 2021
Lead Product(s) : Lidocaine,Heparin Sodium
Therapeutic Area : Urology
Highest Development Status : Phase II
Sponsor : Hyloris Pharmaceuticals
Deal Size : $6.7 million
Deal Type : Collaboration
Lead Product(s) : Ferric Pyrophosphate Citrate,Heparin Sodium
Therapeutic Area : Nephrology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : TRIFERIC is indicated for the replacement of iron to maintain hemoglobin in adult patients with hemodialysis-dependent chronic kidney disease, Safety profile of drug is similar to placebo in controlled clinical trials in patients with end-stage kidney di...
Product Name : Triferic
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
November 16, 2021
Lead Product(s) : Ferric Pyrophosphate Citrate,Heparin Sodium
Therapeutic Area : Nephrology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable